Reshape Biotech

reshapebiotech.com →

-66%

est. 2Y upside i

HealthcareRoboticsAI & MLSeries A

Robots that automate the everyday tasks of microbiologists.

Rank

#1092

Sector

Biotechnology, Lab Automation, Robotics, AI/ML

Est. Liquidity

~6Y

Data Quality

Data: Medium

Reshape Biotech presents a strong upside opportunity for a job seeker, driven by its high growth (270% ARR increase in 2024) in a large and expanding lab automation market.

Last updated: March 10, 2026

Bull (25%)+300%

Reshape Biotech's specialized robots and AI platform achieve strong market penetration, particularly in food, agriculture, and microbial research, leading to rapid revenue growth to $50M+ by 2028. This success attracts an acquisition by a major life sciences tools company at a valuation of $440M (4x current valuation), providing a significant return for common shareholders.

Base (40%)+100%

The company continues to grow steadily, securing its niche in microbiology lab automation and expanding its recurring subscription revenue. It successfully raises a Series B and C, reaching $25M in annual revenue by 2028 and achieving a valuation of $220M (2x current valuation) at a later-stage funding round or modest IPO, offering a moderate return.

Bear (35%)-95%

Slower-than-expected market adoption and aggressive moves by incumbents like Hamilton Robotics lead to missed growth targets. The company struggles to raise its next funding round, resulting in a down round or an acquisition at a valuation of $30M, leaving little to no value for common shareholders after accounting for the $29M in liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $29M in liquidation preferences ahead of common stock.

Dilution Risk

high

As a Series A company with high capital intensity, significant dilution from future funding rounds is likely to fuel R&D and market expansion.

Secondary Liquidity

none

Given its early stage (Series A), there is currently no active secondary market or tender offers for Reshape Biotech equity.

Other — 1 role

View all 1 open roles at Reshape Biotech →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Reshape Biotech's data — designed to show you've done your homework.

  • 1

    “How does Reshape Biotech plan to maintain its competitive edge and differentiate its modular solutions against established players like Hamilton Robotics and Opentrons, especially if they develop similar offerings?”

  • 2

    “With an estimated annual revenue of $13.2M and high growth, what are the key milestones and revenue targets for the next 2-3 years, and what is the strategy to achieve profitability given the high capital intensity?”

  • 3

    “Given the Series A funding and the $29M in total funding, how does the company envision the timeline for a potential liquidity event for employees, and what are the plans to manage future dilution?”

Community

Valuation Sentiment

Our model estimates -66% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.